. 2020 Jun;27(1).
doi: 10.1186/s12929-020-00652-z.

Ab locks for improving the selectivity and safety of antibody drugs

Wen-Wei Lin 1 Yun-Chi Lu 2 Chih-Hung Chuang 3 Tian-Lu Cheng 4 
  • PMID: 32586313
  •     196 References


Monoclonal antibodies (mAbs) are a major targeted therapy for malignancies, infectious diseases, autoimmune diseases, transplant rejection and chronic inflammatory diseases due to their antigen specificity and longer half-life than conventional drugs. However, long-term systemic antigen neutralization by mAbs may cause severe adverse events. Improving the selectivity of mAbs to distinguish target antigens at the disease site from normal healthy tissue and reducing severe adverse events caused by the mechanisms-of-action of mAbs is still a pressing need. Development of pro-antibodies (pro-Abs) by installing a protease-cleavable Ab lock is a novel and advanced recombinant Ab-based strategy that efficiently masks the antigen binding ability of mAbs in the normal state and selectively "turns on" the mAb activity when the pro-Ab reaches the proteolytic protease-overexpressed diseased tissue. In this review, we discuss the design and advantages/disadvantages of different Ab lock strategies, focusing particularly on spatial-hindrance-based and affinity peptide-based approaches. We expect that the development of different masking strategies for mAbs will benefit the local reactivity of mAbs at the disease site, increase the therapeutic efficacy and safety of long-term treatment with mAbs in chronic diseases and even permit scientists to develop Ab drugs for formerly undruggable targets and satisfy the unmet medical needs of mAb therapy.

Keywords: Ab lock; Monoclonal antibody (mAb); adverse events; affinity-based approaches; spatial-hindrance-based approaches.

Improving the efficacy of antibody-based cancer therapies.
P Carter.
Nat Rev Cancer, 2002 Mar 22; 1(2). PMID: 11905803
Highly Cited. Review.
Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.
B Smolarz, J Blasiak, +5 authors, T Szewczyk.
J Exp Clin Cancer Res, 2001 Aug 04; 20(2). PMID: 11484982
Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review.
C Sgro.
Toxicology, 1995 Dec 20; 105(1). PMID: 8638282
Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
Jeffrey Weber.
Oncologist, 2007 Aug 04; 12(7). PMID: 17673617
Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
Lisa C Zaba, Mayte Suárez-Fariñas, +5 authors, James G Krueger.
J Allergy Clin Immunol, 2009 Nov 10; 124(5). PMID: 19895991    Free PMC article.
Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?
Joel R Rosh, Thomas Gross, +2 authors, Jeffrey Hyams.
Inflamm Bowel Dis, 2007 May 08; 13(8). PMID: 17480018
Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy.
Yun-Chi Lu, Chih-Hung Chuang, +11 authors, Tian-Lu Cheng.
PLoS Biol, 2019 Jun 14; 17(6). PMID: 31194726    Free PMC article.
The availability of glucose to CHO cells affects the intracellular lipid-linked oligosaccharide distribution, site occupancy and the N-glycosylation profile of a monoclonal antibody.
Bo Liu, Maureen Spearman, +3 authors, Michael Butler.
J Biotechnol, 2013 Nov 30; 170. PMID: 24286971
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Ganesh Suntharalingam, Meghan R Perry, +4 authors, Nicki Panoskaltsis.
N Engl J Med, 2006 Aug 16; 355(10). PMID: 16908486
Highly Cited.
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
L B A van de Putte, C Atkins, +13 authors, H Kupper.
Ann Rheum Dis, 2004 Apr 15; 63(5). PMID: 15082480    Free PMC article.
Highly Cited.
Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators.
T T Lah, M Cercek, +4 authors, I Daskal.
Clin Cancer Res, 2000 Feb 26; 6(2). PMID: 10690542
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
P A Calabresi, G Giovannoni, +18 authors, AFFIRM and SENTINEL Investigators.
Neurology, 2007 Sep 01; 69(14). PMID: 17761550
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.
M G Wing, T Moreau, +6 authors, A Compston.
J Clin Invest, 1996 Dec 15; 98(12). PMID: 8981930    Free PMC article.
Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders.
K Gijbels, S Masure, H Carton, G Opdenakker.
J Neuroimmunol, 1992 Nov 01; 41(1). PMID: 1334098
Adalimumab: a review of side effects.
Noah Scheinfeld.
Expert Opin Drug Saf, 2005 Jul 14; 4(4). PMID: 16011443
A set of de novo designed parallel heterodimeric coiled coils with quantified dissociation constants in the micromolar to sub-nanomolar regime.
Franziska Thomas, Aimee L Boyle, Antony J Burton, Derek N Woolfson.
J Am Chem Soc, 2013 Mar 13; 135(13). PMID: 23477407
ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis.
Takashi Ohtsuka, Takayuki Shiomi, +6 authors, Yasunori Okada.
Int J Cancer, 2005 Jul 30; 118(2). PMID: 16052521
A coiled-coil masking domain for selective activation of therapeutic antibodies.
Vivian H Trang, Xinqun Zhang, +10 authors, Matthew R Levengood.
Nat Biotechnol, 2019 May 28; 37(7). PMID: 31133742
Rational design of antirheumatic prodrugs specific for sites of inflammation.
Shimobi C Onuoha, Mathieu Ferrari, Daniele Sblattero, Costantino Pitzalis.
Arthritis Rheumatol, 2015 Jun 23; 67(10). PMID: 26097196    Free PMC article.
Efalizumab: a review of events reported during clinical trials and side effects.
Noah Scheinfeld.
Expert Opin Drug Saf, 2006 Mar 01; 5(2). PMID: 16503742
Cellular sources of MMP-7, MMP-13 and MMP-28 in ulcerative colitis.
Timo Rath, Martin Roderfeld, +3 authors, Jürgen Graf.
Scand J Gastroenterol, 2010 Jun 24; 45(10). PMID: 20568971
Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease.
Richard E K Russell, Sarah V Culpitt, +4 authors, Peter J Barnes.
Am J Respir Cell Mol Biol, 2002 Apr 24; 26(5). PMID: 11970913
Development of therapeutic antibodies for the treatment of diseases.
Ruei-Min Lu, Yu-Chyi Hwang, +4 authors, Han-Chung Wu.
J Biomed Sci, 2020 Jan 03; 27(1). PMID: 31894001    Free PMC article.
Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
H Kobayashi, S Fujishiro, T Terao.
Cancer Res, 1994 Dec 15; 54(24). PMID: 7987854
Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke.
D C Anthony, B Ferguson, +3 authors, V H Perry.
Neuropathol Appl Neurobiol, 1997 Nov 19; 23(5). PMID: 9364466
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Elizabeth Tan-Chiu, Greg Yothers, +13 authors, John Bryant.
J Clin Oncol, 2005 Nov 01; 23(31). PMID: 16258083
Highly Cited.
Subendothelial infiltration of neutrophil granulocytes and liberation of matrix-destabilizing enzymes in an experimental model of human neo-intima.
Bernhard Dorweiler, Michael Torzewski, +3 authors, Christian-Friedrich Vahl.
Thromb Haemost, 2008 Feb 19; 99(2). PMID: 18278188
Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers.
Steven Young-Min, Tim Cawston, +5 authors, Ian Griffiths.
Arthritis Rheum, 2007 Oct 02; 56(10). PMID: 17907159
A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab.
N Scheinfeld.
J Dermatolog Treat, 2004 Sep 17; 15(5). PMID: 15370396
Canakinumab for the treatment of chronic obstructive pulmonary disease.
Paola Rogliani, Luigino Calzetta, Josuel Ora, Maria Gabriella Matera.
Pulm Pharmacol Ther, 2015 Feb 11; 31. PMID: 25660162
Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases.
Oran Erster, Jerry M Thomas, +6 authors, Patrick S Daugherty.
J Control Release, 2012 May 29; 161(3). PMID: 22634092    Free PMC article.
A comprehensive review of rituximab therapy in rheumatoid arthritis patients.
Soheil Tavakolpour, Samira Alesaeidi, +5 authors, Arash Jafarieh.
Clin Rheumatol, 2019 Aug 02; 38(11). PMID: 31367943
Cysteine proteinase cathepsin H in tumours and sera of lung cancer patients: relation to prognosis and cigarette smoking.
A Schweiger, A Staib, +5 authors, J Kos.
Br J Cancer, 2000 Mar 25; 82(4). PMID: 10732746    Free PMC article.
Modification of osteopontin and MMP-9 levels in patients with psoriasis on anti-TNF-α therapy.
E Buommino, A De Filippis, +4 authors, Fabio Ayala.
Arch Dermatol Res, 2012 Jun 12; 304(6). PMID: 22684781
Evolving role of uPA/uPAR system in human cancers.
Kathleen Dass, Aamir Ahmad, +2 authors, Fazlul H Sarkar.
Cancer Treat Rev, 2007 Dec 29; 34(2). PMID: 18162327
Highly Cited. Review.
Prognostic role of urokinase-type plasminogen activator in human gliomas.
D W Hsu, J T Efird, E T Hedley-Whyte.
Am J Pathol, 1995 Jul 01; 147(1). PMID: 7604873    Free PMC article.
Natalizumab for multiple sclerosis.
Richard M Ransohoff.
N Engl J Med, 2007 Jun 22; 356(25). PMID: 17582072
MMPs are Involved in Osteoporosis and are Correlated with Cardiovascular Diseases.
Aline Azevedo, Alejandro F Prado, +3 authors, Joao Paulo M Issa.
Curr Pharm Des, 2018 Jun 06; 24(16). PMID: 29865998
Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy.
Howard L Kaufman, Jedd D Wolchok.
J Clin Oncol, 2006 May 20; 24(15). PMID: 16710020
Trastuzumab in the Treatment of Breast Cancer.
Sofia Maximiano, Paulo Magalhães, Mara Pereira Guerreiro, Manuel Morgado.
BioDrugs, 2016 Feb 20; 30(2). PMID: 26892619
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.
N Harbeck, U Alt, +6 authors, M Schmitt.
Clin Cancer Res, 2001 Sep 14; 7(9). PMID: 11555589
Passive antibody therapy for infectious diseases.
Arturo Casadevall, Ekaterina Dadachova, Liise-anne Pirofski.
Nat Rev Microbiol, 2004 Sep 17; 2(9). PMID: 15372080
Highly Cited. Review.
Cathepsin B, L, and D activities in colorectal carcinomas: relationship with clinico-pathological parameters.
A Adenis, G Huet, +3 authors, J P Peyrat.
Cancer Lett, 1995 Sep 25; 96(2). PMID: 7585467
Cathepsin B and cystatins: evidence for a role in cancer progression.
B F Sloane.
Semin Cancer Biol, 1990 Apr 01; 1(2). PMID: 2103490
The utility of monoclonal antibody therapy in renal transplantation.
R Loertscher.
Transplant Proc, 2002 May 30; 34(3). PMID: 12034186
Automated dynamic fed-batch process and media optimization for high productivity cell culture process development.
Franklin Lu, Poh Choo Toh, +4 authors, Jincai Li.
Biotechnol Bioeng, 2012 Jul 07; 110(1). PMID: 22767053
Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.
Matthew T Drake, Bart L Clarke, Merry Jo Oursler, Sundeep Khosla.
Endocr Rev, 2017 Jun 28; 38(4). PMID: 28651365    Free PMC article.
Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains.
I-Ju Chen, Chih-Hung Chuang, +10 authors, Shey-Cherng Tzou.
Sci Rep, 2017 Sep 16; 7(1). PMID: 28912497    Free PMC article.
Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Thomas S Lin.
Clin Lymphoma Myeloma, 2008 Nov 01; 8 Suppl 4. PMID: 18952544
Multiple lessons for multiple sclerosis.
Stephen L Hauser.
N Engl J Med, 2008 Oct 24; 359(17). PMID: 18946071
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Kenneth R Carson, Andrew M Evens, +21 authors, Charles L Bennett.
Blood, 2009 Mar 07; 113(20). PMID: 19264918    Free PMC article.
Highly Cited.
Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
K M King, A Younes.
Expert Rev Anticancer Ther, 2002 Jul 13; 1(2). PMID: 12113023
Prognostic significance of matrix metalloproteinase 7 immunohistochemical expression in colorectal cancer: a meta-analysis.
Haiyan Chen, Yeting Hu, +6 authors, Kefeng Ding.
Int J Clin Exp Med, 2015 Jun 13; 8(3). PMID: 26064217    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.
Hongbin Li, Xiaoqin Ye, +3 authors, Shuang Huang.
J Biol Chem, 2005 Jan 18; 280(11). PMID: 15653692
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.
Luisa Klotz, Joachim Havla, +4 authors, Heinz Wiendl.
Ther Adv Neurol Disord, 2019 Apr 11; 12. PMID: 30967901    Free PMC article.
Highly Cited. Review.
Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.
M L Cuzner, G Opdenakker.
J Neuroimmunol, 1999 Jun 22; 94(1-2). PMID: 10376931
New protein engineering approaches to multivalent and bispecific antibody fragments.
A Plückthun, P Pack.
Immunotechnology, 1997 Jun 01; 3(2). PMID: 9237094
Establishing risk of human experimentation with drugs: lessons from TGN1412.
M J H Kenter, A F Cohen.
Lancet, 2006 Oct 19; 368(9544). PMID: 17046471
Trastuzumab-associated cardiotoxicity.
Deborah L Keefe.
Cancer, 2002 Sep 19; 95(7). PMID: 12237930
The safety and side effects of monoclonal antibodies.
Trevor T Hansel, Harald Kropshofer, +2 authors, Andrew J T George.
Nat Rev Drug Discov, 2010 Mar 23; 9(4). PMID: 20305665
Highly Cited. Review.
Meta-analysis is no substitute for a comprehensive national registry.
Magdalena Dziadzio, Roy Smith.
Clin Rheumatol, 2006 Nov 23; 26(7). PMID: 17115099
Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment.
Lawrence Fong, Eric J Small.
J Clin Oncol, 2008 Oct 08; 26(32). PMID: 18838703
Systematic Review.
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.
Tarek A Yousry, Eugene O Major, +11 authors, David B Clifford.
N Engl J Med, 2006 Mar 03; 354(9). PMID: 16510746    Free PMC article.
Highly Cited.
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
Daniel Tracey, Lars Klareskog, +2 authors, Paul P Tak.
Pharmacol Ther, 2007 Dec 25; 117(2). PMID: 18155297
Highly Cited. Review.
Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.
Feng Ji, Yue-Liang Chen, +3 authors, You-Ming Li.
World J Gastroenterol, 2005 Jun 02; 11(21). PMID: 15929171    Free PMC article.
De-novo and acquired resistance to immune checkpoint targeting.
Nicholas L Syn, Michele W L Teng, Tony S K Mok, Ross A Soo.
Lancet Oncol, 2017 Dec 07; 18(12). PMID: 29208439
Highly Cited. Review.
ADAM 33 gene V4 C/G rs2787094 polymorphism in psoriasis.
R Akcilar, N D Namdar, +2 authors, H Burhan.
Bratisl Lek Listy, 2018 Aug 31; 119(7). PMID: 30160137
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
CAMMS223 Trial Investigators, Alasdair J Coles, +6 authors, P K Tandon.
N Engl J Med, 2008 Oct 24; 359(17). PMID: 18946064
Highly Cited.
Adhesion molecules in breast carcinoma: a challenge to the pathologist.
Claudia Rossetti, Beatriz da Costa Aguiar Alves Reis, +4 authors, Fernando Fonseca.
Rev Assoc Med Bras (1992), 2015 Apr 25; 61(1). PMID: 25909214
Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques.
Elizabeth Gray, Taya Louise Thomas, +2 authors, Seth Love.
J Neuropathol Exp Neurol, 2008 Aug 22; 67(9). PMID: 18716555
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Gillian E Stillfried, Darren N Saunders, Marie Ranson.
Breast Cancer Res, 2007 Jan 30; 9(1). PMID: 17257442    Free PMC article.
Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract.
J A Cohen, D B Weiner, +5 authors, M I Greene.
Oncogene, 1989 Jan 01; 4(1). PMID: 2563577
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.
Pauline A van Schouwenburg, Lotte A van de Stadt, +9 authors, Diana Wouters.
Ann Rheum Dis, 2012 Jul 05; 72(1). PMID: 22759910
Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab.
Andrea G S Buggins, Ghulam J Mufti, +6 authors, Stephen Devereux.
Blood, 2002 Aug 15; 100(5). PMID: 12176892
Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
Oshin Miranda, Mariya Farooqui, Jill M Siegfried.
Cancers (Basel), 2018 Aug 24; 10(9). PMID: 30134579    Free PMC article.
Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study.
Nobuyuki Miyasaka, CHANGE Study Investigators.
Mod Rheumatol, 2008 Mar 12; 18(3). PMID: 18330677    Free PMC article.
Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis.
J Kos, A Sekirnik, +5 authors, B Werle.
Br J Cancer, 2001 Nov 17; 85(8). PMID: 11710834    Free PMC article.
Structural basis of assembly of the human T cell receptor-CD3 complex.
De Dong, Lvqin Zheng, +7 authors, Zhiwei Huang.
Nature, 2019 Aug 29; 573(7775). PMID: 31461748
Highly Cited.
The VEGFR2, COX-2 and MMP-2 polymorphisms are associated with clinical outcome of patients with inoperable non-small cell lung cancer.
Dorota Butkiewicz, Małgorzata Krześniak, +7 authors, Rafał Suwiński.
Int J Cancer, 2015 May 16; 137(10). PMID: 25975224
Serum pro-matrix metalloproteinase-3 as an indicator of disease activity and severity in rheumatoid arthritis: comparison with traditional markers.
Aşkin Ateş, Nuran Türkçapar, +4 authors, Murat Duman.
Rheumatol Int, 2007 Apr 12; 27(8). PMID: 17426976
Secretion of MMP-2 and MMP-9 induced by VEGF autocrine loop correlates with clinical features in childhood acute lymphoblastic leukemia.
Florent Poyer, Bérénice Coquerel, +4 authors, Marek Lamacz.
Leuk Res, 2008 Oct 03; 33(3). PMID: 18829111
ADAM-17 predicts adverse outcome in patients with breast cancer.
P M McGowan, E McKiernan, +7 authors, M J Duffy.
Ann Oncol, 2008 Feb 02; 19(6). PMID: 18238782
The active form of MMP-3 is a marker of synovial inflammation and cartilage turnover in inflammatory joint diseases.
Shu Sun, Anne-Christine Bay-Jensen, +5 authors, Kim Henriksen.
BMC Musculoskelet Disord, 2014 Mar 20; 15. PMID: 24641725    Free PMC article.
VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study.
O Simonetti, G Lucarini, +4 authors, A Offidani.
Int J Immunopathol Pharmacol, 2006 Dec 15; 19(4). PMID: 17166397
Development of a novel albumin-binding prodrug that is cleaved by urokinase-type-plasminogen activator (uPA).
Da-Eun Chung, Felix Kratz.
Bioorg Med Chem Lett, 2006 Aug 01; 16(19). PMID: 16875815
Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response.
Oakley C Olson, Johanna A Joyce.
Nat Rev Cancer, 2015 Nov 26; 15(12). PMID: 26597527
Highly Cited. Review.
Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression.
A M Troy, K Sheahan, +3 authors, D P O'Donoghue.
Eur J Cancer, 2004 Jun 16; 40(10). PMID: 15196548
Differential expression of LFA-1 molecules in non-Hodgkin's lymphoma and lymphoid leukemia.
G Inghirami, R Wieczorek, +3 authors, D M Knowles.
Blood, 1988 Oct 01; 72(4). PMID: 3048446
L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers.
Nancy Gavert, Maralice Conacci-Sorrell, +4 authors, Avri Ben-Ze'ev.
J Cell Biol, 2005 Feb 18; 168(4). PMID: 15716380    Free PMC article.
Highly Cited.
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Chien-Chun Steven Pai, Donald M Simons, +22 authors, Lawrence Fong.
J Clin Invest, 2018 Dec 12; 129(1). PMID: 30530991    Free PMC article.
Expression of ADAM-9 mRNA and protein in human breast cancer.
Caroline O'Shea, Norman McKie, +5 authors, Michael J Duffy.
Int J Cancer, 2003 May 27; 105(6). PMID: 12767059
MMP-13 In-Vivo Molecular Imaging Reveals Early Expression in Lung Adenocarcinoma.
Mathieu Salaün, Jing Peng, +7 authors, Margie L Clapper.
PLoS One, 2015 Jul 21; 10(7). PMID: 26193700    Free PMC article.
Overexpression of progelatinase B/proMMP-9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen.
Elvira Bailón, Estefanía Ugarte-Berzal, +4 authors, Angeles García-Pardo.
J Leukoc Biol, 2014 Aug 01; 96(2). PMID: 25080557
Cardiac toxicity of ErbB2-targeted therapies: what do we know?
Edith A Perez.
Clin Breast Cancer, 2008 Sep 10; 8 Suppl 3. PMID: 18777950
The neu (c-erbB-2) oncogene.
H C Maguire, M I Greene.
Semin Oncol, 1989 Apr 01; 16(2). PMID: 2565604
Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
Yun Yang, Qingcheng Guo, +12 authors, Yajun Guo.
MAbs, 2015 Feb 14; 7(2). PMID: 25679409    Free PMC article.
RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Sai MuraliKrishna Pulukuri, Christopher S Gondi, +4 authors, Jasti S Rao.
J Biol Chem, 2005 Aug 30; 280(43). PMID: 16127174    Free PMC article.
Highly Cited.
Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics.
Marc Feldmann, Sir Ravinder N Maini.
Immunol Rev, 2008 Jul 11; 223. PMID: 18613827
Highly Cited. Review.
Rapid high-throughput characterisation, classification and selection of recombinant mammalian cell line phenotypes using intact cell MALDI-ToF mass spectrometry fingerprinting and PLS-DA modelling.
Jane F Povey, Christopher J O'Malley, +8 authors, C Mark Smales.
J Biotechnol, 2014 May 27; 184. PMID: 24858576
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
Hans-Peter Gerber, May Kung-Sutherland, +11 authors, Iqbal S Grewal.
Blood, 2009 Jan 17; 113(18). PMID: 19147785
Integrin signaling.
F G Giancotti, E Ruoslahti.
Science, 1999 Aug 14; 285(5430). PMID: 10446041
Highly Cited. Review.
Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis.
Vinod Chandran, Richard J Cook, +5 authors, Dafna D Gladman.
Rheumatology (Oxford), 2010 Apr 28; 49(7). PMID: 20421218
Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease.
S D Shapiro.
Am J Respir Crit Care Med, 1994 Dec 01; 150(6 Pt 2). PMID: 7952653
ADAM8 as a novel serological and histochemical marker for lung cancer.
Nobuhisa Ishikawa, Yataro Daigo, +5 authors, Yusuke Nakamura.
Clin Cancer Res, 2004 Dec 30; 10(24). PMID: 15623614
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
Peter C Taylor, Marc Feldmann.
Nat Rev Rheumatol, 2009 Oct 03; 5(10). PMID: 19798034
Highly Cited. Review.
p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.
R M Hudziak, G D Lewis, +3 authors, A Ullrich.
Mol Cell Biol, 1989 Mar 01; 9(3). PMID: 2566907    Free PMC article.
Highly Cited.
Evaluation of Immunogenicity of Nivolumab Monotherapy and Its Clinical Relevance in Patients With Metastatic Solid Tumors.
Shruti Agrawal, Paul Statkevich, +7 authors, Manish Gupta.
J Clin Pharmacol, 2016 Aug 26; 57(3). PMID: 27557786
Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype.
M G Wing, H Waldmann, +2 authors, G Hale.
Ther Immunol, 1995 Aug 01; 2(4). PMID: 9358610
Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
U Winkler, M Jensen, +3 authors, A Engert.
Blood, 1999 Sep 25; 94(7). PMID: 10498591
Highly Cited.
The assessment of matrix metalloproteinase-9 expression and angiogenesis in colorectal cancer.
Eugen Florin Georgescu, Stelian ŞtefăniŢă Mogoantă, +4 authors, Casiana Stănescu.
Rom J Morphol Embryol, 2015 Dec 15; 56(3). PMID: 26662150
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy.
Karl S Peggs, Sergio A Quezada, Alan J Korman, James P Allison.
Curr Opin Immunol, 2006 Feb 09; 18(2). PMID: 16464564
Highly Cited. Review.
Getting specific: monoclonal antibodies in multiple sclerosis.
Andreas Lutterotti, Roland Martin.
Lancet Neurol, 2008 May 20; 7(6). PMID: 18485317
Rituximab-related viral infections in lymphoma patients.
Sercan Aksoy, Hakan Harputluoglu, +4 authors, Ibrahim Barista.
Leuk Lymphoma, 2007 Jul 07; 48(7). PMID: 17613758
Plasminogen activation in human acute leukaemias.
A Scherrer, A Wohlwend, +2 authors, A P Sappino.
Br J Haematol, 1999 Nov 11; 105(4). PMID: 10554801
Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
Joshua M Donaldson, Csaba Kari, +2 authors, John C Williams.
Cancer Biol Ther, 2009 Sep 29; 8(22). PMID: 19783899    Free PMC article.
Cathepsin B: a potential prognostic marker for inflammatory breast cancer.
Mohamed A Nouh, Mona M Mohamed, +4 authors, Bonnie F Sloane.
J Transl Med, 2011 Jan 05; 9. PMID: 21199580    Free PMC article.
Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer.
C Thomssen, M Schmitt, +5 authors, H Graeff.
Clin Cancer Res, 1995 Jul 01; 1(7). PMID: 9816040
Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary.
Rocio S Lopez-Diego, Howard L Weiner.
Nat Rev Drug Discov, 2008 Nov 01; 7(11). PMID: 18974749
Expression, proliferation activity and clinical significance of cathepsin B and cathepsin L in operated lung cancer.
Klaus Kayser, Natalia Richter, +3 authors, Bernd Werle.
Anticancer Res, 2003 Aug 21; 23(3C). PMID: 12926111
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Kenneth R Carson, Daniele Focosi, +4 authors, Charles L Bennett.
Lancet Oncol, 2009 Aug 04; 10(8). PMID: 19647202
Highly Cited. Review.
Comparative sequence specificities of human 72- and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin).
S Netzel-Arnett, Q X Sang, +3 authors, H E Van Wart.
Biochemistry, 1993 Jun 29; 32(25). PMID: 8390857
A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation.
H Lehväslaiho, L Lehtola, L Sistonen, K Alitalo.
EMBO J, 1989 Jan 01; 8(1). PMID: 2565807    Free PMC article.
The Expression and Significance of CXCR5 and MMP-13 in Colorectal Cancer.
Qin Yan, Yin Yuan, +5 authors, Qi Xiaowei.
Cell Biochem Biophys, 2015 Mar 03; 73(1). PMID: 25726157
Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
Luc R Desnoyers, Olga Vasiljeva, +20 authors, Henry B Lowman.
Sci Transl Med, 2013 Oct 18; 5(207). PMID: 24132639
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis.
D Leppert, J Ford, +6 authors, L Kappos.
Brain, 1999 Jan 05; 121 ( Pt 12). PMID: 9874483
Matrix metalloproteinase-9: a novel biomarker for monitoring disease activity in patients with chronic urticaria patients?
S Altrichter, N Boodstein, M Maurer.
Allergy, 2009 Mar 26; 64(4). PMID: 19317840
Therapy: Targeted but not trouble-free: efalizumab and PML.
Eamonn S Molloy, Leonard H Calabrese.
Nat Rev Rheumatol, 2009 Aug 04; 5(8). PMID: 19648939
Matrix metalloproteinases and their role in psoriasis.
Alexandre Mezentsev, Alexander Nikolaev, Sergey Bruskin.
Gene, 2014 Feb 13; 540(1). PMID: 24518811
Cysteine cathepsins and extracellular matrix degradation.
Marko Fonović, Boris Turk.
Biochim Biophys Acta, 2014 Apr 01; 1840(8). PMID: 24680817
Highly Cited. Review.
Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Hiroki Mitoma, Takahiko Horiuchi, Hiroshi Tsukamoto, Naoyasu Ueda.
Cytokine, 2016 Aug 29; 101. PMID: 27567553
The advent of the cytokine storm.
Ian A Clark.
Immunol Cell Biol, 2007 Jun 07; 85(4). PMID: 17551531
JCV detection in multiple sclerosis patients treated with natalizumab.
Saud A Sadiq, Lauren M Puccio, Edward W A Brydon.
J Neurol, 2010 Jan 07; 257(6). PMID: 20052484
Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium.
G Pedersen, T Saermark, T Kirkegaard, J Brynskov.
Clin Exp Immunol, 2009 Jan 13; 155(2). PMID: 19137636    Free PMC article.
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
H Shiomi, Y Eguchi, +2 authors, T Hattori.
Am J Pathol, 2000 Feb 10; 156(2). PMID: 10666386    Free PMC article.
Preclinical studies of a Pro-antibody-drug conjugate designed to selectively target EGFR-overexpressing tumors with improved therapeutic efficacy.
Yun Yang, Qingcheng Guo, +8 authors, Hao Wang.
MAbs, 2016 Jan 14; 8(2). PMID: 26760045    Free PMC article.
Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions.
J A Cossins, J M Clements, +5 authors, C J De Groot.
Acta Neuropathol, 1998 Jan 28; 94(6). PMID: 9444361
Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis.
Marcia L Moss, Liora Sklair-Tavron, Raphael Nudelman.
Nat Clin Pract Rheumatol, 2008 Apr 17; 4(6). PMID: 18414459
Role of matrix metalloproteinase-8 in atherosclerosis.
Sébastien Lenglet, François Mach, Fabrizio Montecucco.
Mediators Inflamm, 2013 Feb 01; 2013. PMID: 23365489    Free PMC article.
T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
Suparno Chakrabarti, Dorothy MacDonald, +7 authors, Donald W Milligan.
Br J Haematol, 2003 Apr 03; 121(1). PMID: 12670340
Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer.
N Sukoh, S Abe, +4 authors, Y Kawakami.
Cancer, 1994 Jul 01; 74(1). PMID: 8004582
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.
Silke Metz, Christian Panke, +11 authors, Ulrich Brinkmann.
Protein Eng Des Sel, 2012 Sep 15; 25(10). PMID: 22976197    Free PMC article.
Targeting the β secretase BACE1 for Alzheimer's disease therapy.
Riqiang Yan, Robert Vassar.
Lancet Neurol, 2014 Feb 22; 13(3). PMID: 24556009    Free PMC article.
Highly Cited. Review.
The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis.
R L Lindberg, C J De Groot, +4 authors, D Leppert.
Brain, 2001 Aug 28; 124(Pt 9). PMID: 11522577
Matrix metalloproteinase-9: its interplay with angiogenic factors in inflammatory bowel diseases.
Malgorzata Matusiewicz, Katarzyna Neubauer, +2 authors, Malgorzata Krzystek-Korpacka.
Dis Markers, 2014 May 08; 2014. PMID: 24803722    Free PMC article.
Increased expression of ADAM family members in human breast cancer and breast cancer cell lines.
Uwe Lendeckel, Jana Kohl, +3 authors, Christoph Röcken.
J Cancer Res Clin Oncol, 2004 Nov 27; 131(1). PMID: 15565459
Therapeutic antibodies for autoimmunity and inflammation.
Andrew C Chan, Paul J Carter.
Nat Rev Immunol, 2010 Apr 24; 10(5). PMID: 20414204
Highly Cited. Review.
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P Look, Wim L J van Putten, +37 authors, John A Foekens.
J Natl Cancer Inst, 2002 Jan 17; 94(2). PMID: 11792750
Highly Cited.
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
Christopher J E Watson, J Andrew Bradley, +9 authors, Roy Calne.
Am J Transplant, 2005 May 13; 5(6). PMID: 15888040
Expression of ADAM15 in lung carcinomas.
A Schütz, W Härtig, +3 authors, G Aust.
Virchows Arch, 2005 Mar 10; 446(4). PMID: 15756594
Overexpression of MMP Family Members Functions as Prognostic Biomarker for Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Fanghui Ren, Ruixue Tang, +6 authors, Gang Chen.
PLoS One, 2015 Aug 14; 10(8). PMID: 26270045    Free PMC article.
Systematic Review.
Prognostic significance of cathepsins B and L in primary human breast cancer.
J A Foekens, J Kos, +7 authors, J G Klijn.
J Clin Oncol, 1998 Mar 21; 16(3). PMID: 9508185
Basement membrane alterations in psoriasis are accompanied by epidermal overexpression of MMP-2 and its inhibitor TIMP-2.
R Fleischmajer, K Kuroda, +6 authors, Y Yamada.
J Invest Dermatol, 2000 Nov 09; 115(5). PMID: 11069613
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.
Scott Plevy, Bruce Salzberg, +9 authors, James Lowder.
Gastroenterology, 2007 Oct 09; 133(5). PMID: 17920064
Antibody therapy of cancer.
Andrew M Scott, Jedd D Wolchok, Lloyd J Old.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437872
Highly Cited. Review.
Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease.
M J Duffy, C Duggan, +2 authors, N J O'Higgins.
Clin Chem, 1998 Jun 13; 44(6 Pt 1). PMID: 9625040
Tumor imaging by means of proteolytic activation of cell-penetrating peptides.
Tao Jiang, Emilia S Olson, +3 authors, Roger Y Tsien.
Proc Natl Acad Sci U S A, 2004 Dec 17; 101(51). PMID: 15601762    Free PMC article.
Highly Cited.
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
Ajay V Maker, Peter Attia, Steven A Rosenberg.
J Immunol, 2005 Nov 23; 175(11). PMID: 16301685    Free PMC article.
Matrix metalloproteinase-19 is expressed by keratinocytes in psoriasis.
Sari Suomela, Arja-Leena Kariniemi, +5 authors, Ulpu Saarialho-Kere.
Acta Derm Venereol, 2003 May 09; 83(2). PMID: 12735638
Immunohistochemical expression of Notch1, Jagged1, NF-κB and MMP-9 in colorectal cancer patients and the relationship to clinicopathological parameters.
Chen-Guo Zheng, Rong Chen, +3 authors, Chun Jin.
Cancer Biomark, 2015 Sep 26; 15(6). PMID: 26406415
Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins.
D C Anderson, T A Springer.
Annu Rev Med, 1987 Jan 01; 38. PMID: 3555290
Highly Cited.
Update on disease-modifying therapies for multiple sclerosis.
Diana L Vargas, William R Tyor.
J Investig Med, 2017 Jan 29; 65(5). PMID: 28130412
Highly Cited. Review.
Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
R Swiercz, J D Wolfe, A Zaher, J Jankun.
Clin Cancer Res, 1998 May 14; 4(4). PMID: 9563880
ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3.
Yoko Mitsui, Satsuki Mochizuki, +7 authors, Yasunori Okada.
Cancer Res, 2006 Oct 19; 66(20). PMID: 17047053
Perfusion seed cultures improve biopharmaceutical fed-batch production capacity and product quality.
William C Yang, Jiuyi Lu, +4 authors, Yao-Ming Huang.
Biotechnol Prog, 2014 Feb 28; 30(3). PMID: 24574326
Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer.
Toru Mukohara.
Chemother Res Pract, 2012 Feb 02; 2011. PMID: 22295205    Free PMC article.
The therapeutic monoclonal antibody market.
Dawn M Ecker, Susan Dana Jones, Howard L Levine.
MAbs, 2014 Dec 23; 7(1). PMID: 25529996    Free PMC article.
Highly Cited. Review.
Ocrelizumab and Other CD20+ B-Cell-Depleting Therapies in Multiple Sclerosis.
Jeffrey M Gelfand, Bruce A C Cree, Stephen L Hauser.
Neurotherapeutics, 2017 Jul 12; 14(4). PMID: 28695471    Free PMC article.
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.
Jasmine Davda, Paul Declerck, +5 authors, Eugenia Kraynov.
J Immunother Cancer, 2019 Apr 18; 7(1). PMID: 30992085    Free PMC article.
TNF-blocking agents and tuberculosis: new drugs illuminate an old topic.
J Keane.
Rheumatology (Oxford), 2005 Mar 03; 44(6). PMID: 15741198
EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions.
D F Stern, M P Kamps.
EMBO J, 1988 Apr 01; 7(4). PMID: 3261240    Free PMC article.
In-Depth Characterization of a Pro-Antibody-Drug Conjugate by LC-MS.
Boning Liu, Huaizu Guo, +12 authors, Hao Wang.
Mol Pharm, 2016 Jul 06; 13(8). PMID: 27377124
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
Gudrun Ratzinger, John L Reagan, +2 authors, James W Young.
Blood, 2002 Oct 24; 101(4). PMID: 12393688
Matrix metalloproteinases: role in arthritis.
Peter S Burrage, Kimberlee S Mix, Constance E Brinckerhoff.
Front Biosci, 2005 Sep 09; 11. PMID: 16146751
Highly Cited. Review.
Determination of protease cleavage site motifs using mixture-based oriented peptide libraries.
B E Turk, L L Huang, E T Piro, L C Cantley.
Nat Biotechnol, 2001 Jul 04; 19(7). PMID: 11433279
Highly Cited.
Design and characterization of a heterodimeric coiled coil that forms exclusively with an antiparallel relative helix orientation.
D L McClain, H L Woods, M G Oakley.
J Am Chem Soc, 2001 Jul 18; 123(13). PMID: 11457033
Up-regulated expression of ADAM17 in human colon carcinoma: co-expression with EGFR in neoplastic and endothelial cells.
Frédérique Blanchot-Jossic, Anne Jarry, +5 authors, Jean-François Mosnier.
J Pathol, 2005 Jul 26; 207(2). PMID: 16041691
Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions.
S Suomela, A L Kariniemi, E Snellman, U Saarialho-Kere.
Exp Dermatol, 2001 May 31; 10(3). PMID: 11380613
[Expression of genes for metalloproteinases (MMP-1, MMP-2, MMP-9, and MMP-12) associated with psoriasis].
N L Starodubtseva, V V Sobolev, +2 authors, S A Bruskin.
Genetika, 2011 Nov 29; 47(9). PMID: 22117411
The ADAMs: signalling scissors in the tumour microenvironment.
Gillian Murphy.
Nat Rev Cancer, 2008 Nov 14; 8(12). PMID: 19005493
Highly Cited. Review.
ADAM33 as a psoriasis susceptibility gene in the Han population of northeastern China.
Jing Zhou, Donglin Sun, +3 authors, Yuzhen Li.
Dermatology, 2012 Jan 25; 223(4). PMID: 22269827
Identification of a monoclonal antibody specific for a murine T3 polypeptide.
O Leo, M Foo, +2 authors, J A Bluestone.
Proc Natl Acad Sci U S A, 1987 Mar 01; 84(5). PMID: 2950524    Free PMC article.
Highly Cited.
Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
Aiqun Nielsen, Christopher J Scarlett, +4 authors, Ross C Smith.
J Gastroenterol Hepatol, 2005 Feb 03; 20(2). PMID: 15683429
Immunochemical analysis of cathepsin B in lung tumours: an independent prognostic factor for squamous cell carcinoma patients.
B Werle, H Lötterle, +8 authors, E Spiess.
Br J Cancer, 1999 Oct 03; 81(3). PMID: 10507778    Free PMC article.
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
Johan Askling, C Michael Fored, +12 authors, Nils Feltelius.
Arthritis Rheum, 2005 Jun 30; 52(7). PMID: 15986370
Coiled coils: a highly versatile protein folding motif.
P Burkhard, J Stetefeld, S V Strelkov.
Trends Cell Biol, 2001 Feb 13; 11(2). PMID: 11166216
Highly Cited. Review.
Ventricular bigeminal rhythm associated with trastuzumab: A potential cardiac side effect.
Mustafa Karaca, Hakan Kocoglu, +6 authors, Orhan Kemal Yucel.
J Cancer Res Ther, 2018 Jul 05; 14(Supplement). PMID: 29970721
Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis.
M Kawaguchi, Y Mitsuhashi, S Kondo.
Br J Dermatol, 2005 May 13; 152(5). PMID: 15888146
Matrix metalloproteinases as biomarkers of disease: updates and new insights.
Emanuela Galliera, Lorenza Tacchini, Massimiliano M Corsi Romanelli.
Clin Chem Lab Med, 2014 Aug 26; 53(3). PMID: 25153404
Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction.
Mark Wing.
J Immunotoxicol, 2008 Apr 03; 5(1). PMID: 18382853
Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S.
Lisa Sevenich, Robert L Bowman, +10 authors, Johanna A Joyce.
Nat Cell Biol, 2014 Aug 05; 16(9). PMID: 25086747    Free PMC article.
Highly Cited.
CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
G Hale, P Jacobs, +14 authors, H Waldmann.
Bone Marrow Transplant, 2000 Aug 05; 26(1). PMID: 10918407
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
J A Gormley, S M Hegarty, +9 authors, S A Olwill.
Br J Cancer, 2011 Oct 13; 105(10). PMID: 21989182    Free PMC article.
Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy.
Imran Haider, Mary Cahill.
Hematology, 2005 Mar 15; 9(5-6). PMID: 15763982
Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
Simon D J Gibbs, David A Westerman, +2 authors, H Miles Prince.
Br J Haematol, 2005 Jun 29; 130(1). PMID: 15982349
Expression and significance of HER family receptors in neuroblastic tumors.
Ewa Izycka-Swieszewska, Agnieszka Wozniak, +7 authors, Janusz Limon.
Clin Exp Metastasis, 2011 Jan 05; 28(3). PMID: 21203803